A phase Ib, randomised, double-blind, placebo-controlled, multiple-dose escalation study evaluating the safety, tolerability and pharmacokinetics of NSI-189 in patients with major depressive disorder.
Phase of Trial: Phase I
Latest Information Update: 12 May 2016
At a glance
- Drugs NSI 189 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Neuralstem
- 12 May 2016 Results published in a Neuralstem media release.
- 08 Dec 2015 Results of this trial were published in Molecular Psychiatry, according to a Neuralstem media release.
- 08 Dec 2015 Results published in a Neuralstem media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History